Sarepta Therapeutics Inc SRPT

NAS: SRPT | ISIN: US8036071004   30/04/2025
62,40 USD (+2,55%)
(+2,55%)   30/04/2025
Grafiek Sarepta Therapeutics Inc Grafiek Sarepta Therapeutics Inc
dinsdag 6 mei 2025, 22:00
Kwartaalcijfers (1ste kwartaal)

Sarepta Therapeutics Inc in het nieuws

12 april 2025 · SRPT Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm · Persbericht

29 mei 2024 · Sarepta Therapeutics Set to Join S&P MidCap 400 · Persbericht

5 november 2023 · ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SRPT · Persbericht

3 november 2023 · SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT · Persbericht

30 augustus 2023 · Quest Diagnostics Granted FDA Breakthrough Designation for its Adeno-associated virus (AAV) Test · Persbericht

18 maart 2021 · Sarepta Therapeutics’ Investigational Gene Therapy SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E Shows Sustained Expression and Functional Improvements 2 Years After Administration · Persbericht

15 maart 2021 · Sarepta Therapeutics to Present Results from its Gene Therapy and RNA Platforms at the 2021 Annual MDA Clinical and Scientific Conference · Persbericht

25 februari 2021 · Sarepta Therapeutics Announces FDA Approval of AMONDYS 45™ (casimersen) Injection for the Treatment of Duchenne Muscular Dystrophy (DMD) in Patients Amenable to Skipping Exon 45 · Persbericht

24 februari 2021 · Sarepta Therapeutics to Present at Upcoming Investor Conferences · Persbericht

22 februari 2021 · Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2020 Financial Results and Recent Corporate Developments on March 1, 2021 · Persbericht

Profiel Sarepta Therapeutics Inc

Biotechnologie
Fabricage van farmaceutische preparaten
Gezondheidstechnologie
Productie

Website: www.sarepta.com

Hoofdzetel: Cambridge, Massachusetts vlag Verenigde Staten

CEO: Douglas Ingram

Werknemers: 1.326

Mijn selecties